(Q39281721)

English

Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma

scientific article published on 10 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Masahiro Murakami

1

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Songji Zhao

2

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Yan Zhao

3

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Nusrat Fatema Chowdhury

4

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Wenwen Yu

5

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Ken-Ichi Nishijima

6

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Mitsuyoshi Takiguchi

7

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Nagara Tamaki

8

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Yuji Kuge

9

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

publication date

10 September 2012

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

International Journal of Oncology

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

41

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

5

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

1593-1600

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Biomarkers in tumor angiogenesis and anti-angiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Biomarkers predicting tumor response and evasion to anti-angiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Normalization of the vasculature for treatment of cancer and other diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Renal cell carcinoma: molecularly targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Targeting the tumour vasculature: insights from physiological angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Combination targeted therapy in advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Vascular damaging agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Angiogenesis as a therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Angiogenesis in health and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Tumor angiogenesis: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

10 September 2017

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

14 September 2017

Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

14 September 2017

Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

14 September 2017

Renal cell carcinoma: management of advanced disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

25 September 2017

Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

21 August 2018

Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

21 August 2018

Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

21 August 2018

Fully automated one-pot synthesis of [18F]fluoromisonidazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

21 August 2018

Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

21 August 2018

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583814

21 August 2018

Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis. A boost for tumor starvation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965141

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3892/IJO.2012.1624

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39281721&oldid=1818026850"